Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. GENFIT
  6. Summary
    GNFT   FR0004163111

GENFIT

(GNFT)
  Report
Real-time Quote. Real-time Euronext Paris - 10/22 11:35:20 am
3.2 EUR   -1.54%
10/20European ADRs Move Slightly Higher in Wednesday Trading
MT
10/19GENFIT : Corporate Presentation - October 2021
PU
10/14European ADRs Climb Higher in Thursday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
3.204(c) 3.19(c) 3.236(c) 3.25(c) 3.2(c) Last
79 635 34 031 57 296 31 437 67 912 Volume
-1.35% -0.44% +1.44% +0.43% -1.54% Change
More quotes
Estimated financial data (e)
Sales 2021 7,50 M 8,73 M 8,73 M
Net income 2021 -47,9 M -55,8 M -55,8 M
Net Debt 2021 87,0 M 101 M 101 M
P/E ratio 2021 -2,02x
Yield 2021 -
Sales 2022 8,23 M 9,57 M 9,57 M
Net income 2022 -58,7 M -68,3 M -68,3 M
Net Debt 2022 28,4 M 33,0 M 33,0 M
P/E ratio 2022 -3,45x
Yield 2022 -
Capitalization 146 M 170 M 170 M
EV / Sales 2021 31,1x
EV / Sales 2022 21,2x
Nbr of Employees 122
Free-Float 94,4%
More Financials
Company
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the... 
More about the company
Ratings of GENFIT
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about GENFIT
10/20European ADRs Move Slightly Higher in Wednesday Trading
MT
10/19GENFIT : Corporate Presentation - October 2021
PU
10/14European ADRs Climb Higher in Thursday Trading
MT
09/30GLOBAL MARKETS LIVE : Boeing, Walgreens, Dufry, M&S, Novartis...
09/30GENFIT : HC Wainwright Trims Price Target on Genfit to $7 From $8, Keeps Neutral Rating
MT
09/29GENFIT : 2021 GENFIT Half Year Business and Financial Report
PU
09/29GENFIT : Swings to Surprise First-Half Profit but Revenue Drops Almost 42%
MT
09/29GENFIT : Cash and cash equivalents totaled €104 million as of June 30, 2021 (including €11..
PU
09/29GENFIT : Reports First Half-Year 2021 Financial Results and Provides Corporate Update
AQ
09/24European ADRs Move Lower in Friday Trading
MT
09/16European ADRs Move Lower in Thursday Trading
MT
08/31European ADRs Move Lower in Tuesday Trading
MT
08/18European ADRs Move Slightly Higher in Wednesday Trading
MT
08/16European ADRs Move Lower in Monday Trading
MT
08/03European ADRs Move Higher in Tuesday Trading
MT
More news
News in other languages on GENFIT
10/20Les ADR européens progressent légèrement dans les échanges de mercredi
10/14Les ADR européens grimpent dans la journée de jeudi
09/30GENFIT : du potentiel, Oddo confirme son conseil
09/30GENFIT : dans le vert au premier semestre grâce à la restructuration de la dette convertib..
09/30Un été pour rien ?
More news
Analyst Recommendations on GENFIT
More recommendations
Chart GENFIT
Duration : Period :
GENFIT Technical Analysis Chart | GNFT | FR0004163111 | MarketScreener
Technical analysis trends GENFIT
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,20 €
Average target price 9,50 €
Spread / Average Target 197%
EPS Revisions
Managers and Directors
Pascal Prigent CEO & EVP-Marketing & Development
Thomas Baetz Chief Financial Officer
Jean-François Mouney Chairman
Carol L. Addy Chief Medical Officer
Dean W. Hum Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
GENFIT-19.84%170
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455